Using validation sets for outcomes and exposure to infection in vaccine field studies.

Methods of adjusting for bias in estimates due to mismeasured or missing covariates and outcomes through the use of validation sets have been developed in many types of health studies. These methods can be employed for the efficient design and analysis of vaccine studies as well. On the one hand, nonspecific case definitions can lead to attenuated efficacy and effectiveness estimates, but confirmation by culture or a quick test of the infectious agent is also expensive and difficult. On the other hand, data on exposure to infection can influence estimates of vaccine efficacy, but good data on exposure are difficult to obtain. In this paper, the authors show how use of small validation sets can correct the bias of the estimates obtained from a large main study while maintaining efficiency. They illustrate the approach for outcomes using the example of influenza vaccine efficacy and effectiveness trials and illustrate the approach for exposure to infection using the example of a human immunodeficiency virus vaccine trial. The authors discuss challenges posed by infectious diseases in the use of currently available methods. Development of these efficient designs and methods of analysis for vaccine field studies will improve estimation of vaccine efficacy for both susceptibility and infectiousness, as well as estimation of indirect and overall effects of vaccination in community trials.

[1]  G T Golm,et al.  Semi-parametric models for mismeasured exposure information in vaccine trials. , 1998, Statistics in medicine.

[2]  Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial. , 1999, JAMA.

[3]  J. Robins,et al.  Semiparametric regression estimation in the presence of dependent censoring , 1995 .

[4]  M. Halloran,et al.  Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field. , 1994, Statistics in medicine.

[5]  L. Magder,et al.  Logistic regression when the outcome is measured with uncertainty. , 1997, American journal of epidemiology.

[6]  Nicole A. Lazar,et al.  Statistical Analysis With Missing Data , 2003, Technometrics.

[7]  M E Halloran,et al.  A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines. , 1999, Statistics in medicine.

[8]  Nicholas P. Jewell,et al.  AIDS epidemiology : methodological issues , 1993 .

[9]  M E Halloran,et al.  Study designs for dependent happenings. , 1991, Epidemiology.

[10]  Thomas R. Fleming,et al.  Auxiliary outcome data and the mean score method , 1994 .

[11]  J E White,et al.  A two stage design for the study of the relationship between a rare exposure and a rare disease. , 1982, American journal of epidemiology.

[12]  Margaret S. Pepe,et al.  A mean score method for missing and auxiliary covariate data in regression models , 1995 .

[13]  R. Prentice.  Covariate measurement errors and parameter estimation in a failure time regression model , 1982 .

[14]  R. J. Hayes,et al.  Design and analysis issues in cluster-randomized trials of interventions against infectious diseases , 2000, Statistical methods in medical research.

[15]  Raymond J. Carroll,et al.  Semiparametric Estimation in Logistic Measurement Error Models , 1989 .

[16]  D. Ruppert,et al.  Measurement Error in Nonlinear Models , 1995 .

[17]  F. Hayden,et al.  The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. , 1998, The New England journal of medicine.

[18]  M E Halloran,et al.  Study designs for evaluating different efficacy and effectiveness aspects of vaccines. , 1997, American journal of epidemiology.

[19]  James M. Robins,et al.  Semiparametric Regression for Repeated Outcomes With Nonignorable Nonresponse , 1998 .

[20]  Semiparametric Methods for Multiple Exposure Mismeasurement and a Bivariate Outcome in HIV Vaccine Trials , 1999, Biometrics.

[21]  R. Prentice.  Surrogate endpoints in clinical trials: definition and operational criteria. , 1989, Statistics in medicine.

[22]  K C Cain,et al.  Logistic regression analysis and efficient design for two-stage studies. , 1988, American journal of epidemiology.

[23]  Thomas R. Fleming,et al.  A Nonparametric Method for Dealing with Mismeasured Covariate Data , 1991 .

[24]  S Greenland,et al.  Analytic methods for two-stage case-control studies and other stratified designs. , 1991, Statistics in medicine.

[25]  Lihan K. Yan,et al.  Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. , 2000, The Journal of pediatrics.

[26]  James M. Robins,et al.  Semiparametric efficient estimation of a conditional density with missing or mismeasured covariates , 1995 .

[27]  D. Rubin.  INFERENCE AND MISSING DATA , 1975 .

[28]  J. Robins,et al.  Estimation of Regression Coefficients When Some Regressors are not Always Observed , 1994 .

[29]  J. Robins,et al.  Analysis of semiparametric regression models for repeated outcomes in the presence of missing data , 1995 .

[30]  Margaret S. Pepe,et al.  Inference using surrogate outcome data and a validation sample , 1992 .

[31]  M. Halloran,et al.  Design and interpretation of vaccine field studies. , 1999, Epidemiologic reviews.

[32]  J. Wittes,et al.  Surrogate endpoints in clinical trials: cardiovascular diseases. , 1989, Statistics in medicine.

[33]  Norman E. Breslow,et al.  Maximum Likelihood Estimation of Logistic Regression Parameters under Two‐phase, Outcome‐dependent Sampling , 1997 .

[34]  M E Halloran,et al.  Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[35]  M E Halloran,et al.  Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. , 2000, Vaccine.

[36]  L P Zhao,et al.  Designs and analysis of two-stage studies. , 1992, Statistics in medicine.

[37]  M E Halloran,et al.  Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy. , 1998, Statistics in medicine.

[38]  Norman E. Breslow,et al.  Logistic regression for two-stage case-control data , 1988 .

[39]  A. Monto,et al.  Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. , 1993, The Journal of infectious diseases.

[40]  M. Wulfsohn,et al.  Modeling the Relationship of Survival to Longitudinal Data Measured with Error. Applications to Survival and CD4 Counts in Patients with AIDS , 1995 .

[41]  J. Robins,et al.  Recovery of Information and Adjustment for Dependent Censoring Using Surrogate Markers , 1992 .